Field Medical

Executive Summary

Field Medical is a private medical device company developing a next-generation pulsed field ablation (PFA) system for treating cardiac arrhythmias such as atrial fibrillation and ventricular tachycardia. Unlike conventional thermal ablation methods that use heat or cold, Field Medical's technology delivers targeted electrical fields to ablate heart tissue, potentially reducing damage to surrounding structures and improving patient outcomes. The company was founded in 2018 and is headquartered in San Diego, California, positioning itself in a competitive but rapidly growing segment of the electrophysiology market. With the global AFib ablation market expected to exceed $10 billion by 2030, Field Medical's non-thermal approach offers a promising alternative that could enhance procedural safety and efficacy. The company is still in the early stages, with limited public information on funding rounds or clinical milestones. However, its focus on pulsed field ablation positions it among a wave of innovators seeking to challenge established players like Medtronic and Boston Scientific. Key upcoming catalysts include the initiation of first-in-human studies, which will provide initial clinical evidence, and potential regulatory submissions (CE mark or FDA IDE). Given the competitive landscape and the need for differentiation, Field Medical's success hinges on demonstrating superior safety and efficacy in clinical trials. The company's private status and limited disclosed progress suggest a moderate conviction in its near-term prospects, but the addressable market and technology promise could yield significant upside.

Upcoming Catalysts (preview)

• H2 2026First-in-Human Clinical Trial Initiation70% success
• Q4 2026Series A or B Funding Round60% success
• H1 2027FDA IDE Approval for Pivotal Study40% success